Fezolinetant

Fezolinetant
Clinical data
Trade names	Veozah, Veoza
Other names	ESN-364
AHFS/Drugs.com	Monograph
MedlinePlus	a623051
License data	US DailyMed: Fezolinetant;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	G02CX06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	51%[unreliable medical source?]
Metabolism	CYP1A2, (CYP2C9, CYP2C19 to lesser extent)
Metabolites	ES259564
Elimination half-life	9.6h
Excretion	Urine 76.9%, feces 14.7%[unreliable medical source?]
Identifiers
	IUPAC name (4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone;
CAS Number	1629229-37-3;
PubChem CID	117604931;
DrugBank	DB15669;
ChemSpider	58828046;
UNII	83VNE45KXX;
KEGG	D11976;
ChEBI	CHEBI:229236;
ChEMBL	ChEMBL3608680;
Chemical and physical data
Formula	C16H15FN6OS
Molar mass	358.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C;
	InChI InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3/t9-/m1/s1; Key:PPSNFPASKFYPMN-SECBINFHSA-N;

Fezolinetant, sold under the brand name Veozah among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause.^[2]^[8] It is a small-molecule, orally active, selective neurokinin-3 (NK₃) receptor antagonist which is under development by for the treatment of sex hormone-related disorders.^{[medical citation needed]} It is taken by mouth.^[2] It is developed by Astellas Pharma which acquired it from Ogeda (formerly Euroscreen) in April 2017.^[9]^[10]^[11]

The most common side effects include abdominal pain, diarrhea, insomnia, back pain, hot flush and elevated hepatic transaminases.^[8]

Fezolinetant was approved for medical use in the United States in May 2023,^[8] and in the European Union in December 2023.^[3]^[4] Fezolinetant is the first neurokinin 3 (NK3) receptor antagonist approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes from menopause.^[8] The FDA considers it to be a first-in-class medication.^[12]

^ ^a ^b "Veoza APMDS". Therapeutic Goods Administration (TGA). 6 March 2024. Retrieved 7 March 2024.
^ ^a ^b ^c ^d ^e "Veozah – fezolinetant tablet, film coated". DailyMed. 19 May 2023. Archived from the original on 25 May 2023. Retrieved 24 May 2023.
^ ^a ^b "Veoza EPAR". European Medicines Agency (EMA). 7 December 2023. Archived from the original on 26 December 2023. Retrieved 27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ ^a ^b "Veoza PI". Union Register of medicinal products. 12 December 2023. Archived from the original on 13 December 2023. Retrieved 26 December 2023.
^ "Fezolinetant". Archived from the original on 7 July 2023. Retrieved 7 July 2023.
^ "Pharmacokinetic Study of Fezolinetant - an Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects". 15 April 2022. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
^ "Fezolinetant". DrugBank.com. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
^ ^a ^b ^c ^d "FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause". U.S. Food and Drug Administration (FDA) (Press release). 12 May 2023. Archived from the original on 13 May 2023. Retrieved 13 May 2023. This article incorporates text from this source, which is in the public domain.
^ "Astellas to Acquire Ogeda SA" (Press release). Astellas Pharma. Archived from the original on 5 November 2021. Retrieved 5 November 2021 – via PR Newswire.
^ Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, et al. (July 2015). "Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)". ACS Medicinal Chemistry Letters. 6 (7): 736–740. doi:10.1021/acsmedchemlett.5b00117. PMC 4499830. PMID 26191358.
^ "Fezolinetant – Ogeda". AdisInsight. Archived from the original on 5 November 2021. Retrieved 5 November 2021.
^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.

[Veoza_APMDS-1] "Veoza APMDS". Therapeutic Goods Administration (TGA). 6 March 2024. Retrieved 7 March 2024.

[Veozah_FDA_label-2] "Veozah – fezolinetant tablet, film coated". DailyMed. 19 May 2023. Archived from the original on 25 May 2023. Retrieved 24 May 2023.

[Veoza_EPAR-3] "Veoza EPAR". European Medicines Agency (EMA). 7 December 2023. Archived from the original on 26 December 2023. Retrieved 27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Veoza_PI-4] "Veoza PI". Union Register of medicinal products. 12 December 2023. Archived from the original on 13 December 2023. Retrieved 26 December 2023.

[5] "Fezolinetant". Archived from the original on 7 July 2023. Retrieved 7 July 2023.

[6] "Pharmacokinetic Study of Fezolinetant - an Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects". 15 April 2022. Archived from the original on 7 July 2023. Retrieved 7 July 2023.

[7] "Fezolinetant". DrugBank.com. Archived from the original on 7 July 2023. Retrieved 7 July 2023.

[FDA_PR_20230512-8] "FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause". U.S. Food and Drug Administration (FDA) (Press release). 12 May 2023. Archived from the original on 13 May 2023. Retrieved 13 May 2023. This article incorporates text from this source, which is in the public domain.

[PRNewswire-9] "Astellas to Acquire Ogeda SA" (Press release). Astellas Pharma. Archived from the original on 5 November 2021. Retrieved 5 November 2021 – via PR Newswire.

[Hoveyda-Fraser2015-10] Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, et al. (July 2015). "Optimization of Novel Antagonists to the Neurokinin‑3 Receptor for the Treatment of Sex-Hormone Disorders (Part II)". ACS Medicinal Chemistry Letters. 6 (7): 736–740. doi:10.1021/acsmedchemlett.5b00117. PMC 4499830. PMID 26191358.

[AdisInsight-11] "Fezolinetant – Ogeda". AdisInsight. Archived from the original on 5 November 2021. Retrieved 5 November 2021.

[12] New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]